151 related articles for article (PubMed ID: 32343749)
41. Circulating cell-free DNA: A potential biomarker to differentiate inflammation and infection during radiochemotherapy.
Zwirner K; Hilke FJ; Demidov G; Ossowski S; Gani C; Rieß O; Zips D; Welz S; Schroeder C
Radiother Oncol; 2018 Dec; 129(3):575-581. PubMed ID: 30097252
[TBL] [Abstract][Full Text] [Related]
42. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
43. Feasibility Analysis of Cell-Free DNA Derived from Plasma of Lung Cancer Patients for Next-Generation Sequencing.
Jiang X; Li H; Liu J; Sun H; Zhang L; Li W; Yao J; Cheng Y
Biopreserv Biobank; 2020 Apr; 18(2):117-121. PubMed ID: 32083487
[No Abstract] [Full Text] [Related]
44. Combination of Circulating Cell-Free DNA and Positron Emission Tomography to Distinguish Non-Small Cell Lung Cancer from Tuberculosis.
Zheng W; Quan B; Gao G; Zhang P; Huang L
Lab Med; 2023 Mar; 54(2):130-141. PubMed ID: 36106407
[TBL] [Abstract][Full Text] [Related]
45. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
46. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
47. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer.
Palmero R; Taus A; Viteri S; Majem M; Carcereny E; Garde-Noguera J; Felip E; Nadal E; Malfettone A; Sampayo M; Riva F; Nagy RJ; Lanman RB; Faull I; Dix D; Karachaliou N; Rosell R
JCO Precis Oncol; 2021 Nov; 5():93-102. PubMed ID: 34994593
[TBL] [Abstract][Full Text] [Related]
48. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis.
Leng S; Zheng J; Jin Y; Zhang H; Zhu Y; Wu J; Xu Y; Zhang P
Clin Chim Acta; 2018 Feb; 477():160-165. PubMed ID: 29113814
[TBL] [Abstract][Full Text] [Related]
49. The Dynamic Use of
Macías M; Alegre E; Alkorta-Aranburu G; Patiño-García A; Mateos B; Andueza MP; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; González Á
Dis Markers; 2019; 2019():7954921. PubMed ID: 30809319
[TBL] [Abstract][Full Text] [Related]
50. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
Ai B; Liu H; Huang Y; Peng P
Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
[TBL] [Abstract][Full Text] [Related]
51. Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung.
Schilder RJ; Goldberg M; Millenson MM; Movsas B; Rogatko A; Rogers B; Langer CJ
Lung Cancer; 2000 Jan; 27(1):37-45. PubMed ID: 10672782
[TBL] [Abstract][Full Text] [Related]
52. Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data.
Chen H; Wang A; Wang J; He Z; Mao Y; Liu L
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1867-1876. PubMed ID: 32221744
[TBL] [Abstract][Full Text] [Related]
53. The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA.
Henriksen TV; Reinert T; Christensen E; Sethi H; Birkenkamp-Demtröder K; Gögenur M; Gögenur I; Zimmermann BG; ; Dyrskjøt L; Andersen CL
Mol Oncol; 2020 Aug; 14(8):1670-1679. PubMed ID: 32471011
[TBL] [Abstract][Full Text] [Related]
54. Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis.
Reckamp KL; Patil T; Kirtane K; Rich TA; Espenschied CR; Weipert CM; Raymond VM; Santana-Davila R; Doebele RC; Baik CS
Clin Lung Cancer; 2020 Nov; 21(6):545-552.e1. PubMed ID: 32665165
[TBL] [Abstract][Full Text] [Related]
55. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
56. Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort.
Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Trejo Rosales R; Rojas L; Cruz-Rico G; Nagy R; Cabrera L; Vargas C; Saam J; Barrón F; Arrieta O
Oncology; 2021; 99(8):539-546. PubMed ID: 33902046
[TBL] [Abstract][Full Text] [Related]
57. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer.
Choi NC; Fischman AJ; Niemierko A; Ryu JS; Lynch T; Wain J; Wright C; Fidias P; Mathisen D
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1024-35. PubMed ID: 12419428
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of Changes in Circulating Cell-Free DNA as an Early Predictor of Response to Chemoradiation in Rectal Cancer-A Pilot Study.
Ong WL; Lunca S; Morarasu S; Musina AM; Puscasu A; Iacob S; Iftincai I; Marinca A; Ivanov I; Roata CE; Velenciuc N; Dimofte G
Medicina (Kaunas); 2023 Sep; 59(10):. PubMed ID: 37893461
[No Abstract] [Full Text] [Related]
59. Comparison of circulating DNA in malignant neoplasia from diverse locations: Investigating a diagnostic role.
Kumari S; Mishra S; Husain N; Verma T; Tiwari V; Kaif M; Agarwal A; Rastogi M; Shukla S; Sonkar AA
Indian J Pathol Microbiol; 2022; 65(1):93-99. PubMed ID: 35074971
[TBL] [Abstract][Full Text] [Related]
60. Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma.
Raman L; Van der Linden M; Van der Eecken K; Vermaelen K; Demedts I; Surmont V; Himpe U; Dedeurwaerdere F; Ferdinande L; Lievens Y; Claes K; Menten B; Van Dorpe J
Genome Med; 2020 Apr; 12(1):35. PubMed ID: 32317009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
